Literature DB >> 16502128

Uremic toxin and bone metabolism.

Yoshiko Iwasaki1, Hideyuki Yamato, Tomoko Nii-Kono, Ayako Fujieda, Motoyuki Uchida, Atsuko Hosokawa, Masaru Motojima, Masafumi Fukagawa.   

Abstract

Patients with end-stage renal disease (ESRD) develop various kinds of abnormalities in bone and mineral metabolism, widely known as renal osteodystrophy (ROD). Although the pathogenesis of ESRD may be similar in many patients, the response of the bone varies widely, ranging from high to low turnover. ROD is classified into several types, depending on the status of bone turnover, by histomorphometric analysis using bone biopsy samples [1,2]. In the mild type, bone metabolism is closest to that of persons with normal renal function. In osteitis fibrosa, bone turnover is abnormally activated. This is a condition of high-turnover bone. A portion of the calcified bone loses its lamellar structure and appears as woven bone. In the cortical bone also, bone resorption by osteoclasts is active, and a general picture of bone marrow tissue infiltration and the formation of cancellous bone can be observed. In osteomalacia, the bone surface is covered with uncalcified osteoid. This condition is induced by aluminum accumulation or vitamin D deficiency. The mixed type possesses characteristics of both osteitis fibrosa and osteomalacia. The bone turnover is so markedly accelerated that calcification of the osteoid cannot keep pace. In the adynamic bone type, bone resorption and bone formation are both lowered. While bone turnover is decreased, there is little osteoid. The existence of these various types probably accounts for the diversity in degree of renal impairment, serum parathyroid hormone (PTH) level, and serum vitamin D level in patients with ROD. However, all patients share a common factor, i.e., the presence of a uremic condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16502128     DOI: 10.1007/s00774-005-0667-7

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  30 in total

Review 1.  Review on uremic toxins: classification, concentration, and interindividual variability.

Authors:  Raymond Vanholder; Rita De Smet; Griet Glorieux; Angel Argilés; Ulrich Baurmeister; Philippe Brunet; William Clark; Gerald Cohen; Peter Paul De Deyn; Reinhold Deppisch; Beatrice Descamps-Latscha; Thomas Henle; Achim Jörres; Horst Dieter Lemke; Ziad A Massy; Jutta Passlick-Deetjen; Mariano Rodriguez; Bernd Stegmayr; Peter Stenvinkel; Ciro Tetta; Christoph Wanner; Walter Zidek
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

2.  Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts.

Authors:  M S Wagner; S Stracke; P M Jehle; F Keller; D Zellner; D J Baylink; S Mohan
Journal:  Nephron       Date:  2000-02       Impact factor: 2.847

3.  Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells.

Authors:  Masaru Motojima; Atsuko Hosokawa; Hideyuki Yamato; Takamura Muraki; Toshimasa Yoshioka
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  H2O2-derived free radicals treated fibronectin substratum reduces the bone nodule formation of rat calvarial osteoblast.

Authors:  H Suzuki; M Hayakawa; K Kobayashi; H Takiguchi; Y Abiko
Journal:  Mech Ageing Dev       Date:  1997-11       Impact factor: 5.432

6.  Oxidative stress modulates osteoblastic differentiation of vascular and bone cells.

Authors:  N Mody; F Parhami; T A Sarafian; L L Demer
Journal:  Free Radic Biol Med       Date:  2001-08-15       Impact factor: 7.376

7.  Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.

Authors:  T Niwa; M Ise
Journal:  J Lab Clin Med       Date:  1994-07

8.  Characterization of uremic toxin transport by organic anion transporters in the kidney.

Authors:  Tsuneo Deguchi; Hiroyuki Kusuhara; Akira Takadate; Hitoshi Endou; Masaki Otagiri; Yuichi Sugiyama
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

9.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function.

Authors:  G Hercz; Y Pei; C Greenwood; A Manuel; C Saiphoo; W G Goodman; G V Segre; S Fenton; D J Sherrard
Journal:  Kidney Int       Date:  1993-10       Impact factor: 10.612

10.  Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure.

Authors:  Masami Satoh; Hideo Hayashi; Maki Watanabe; Kyoko Ueda; Hideyuki Yamato; Toshimasa Yoshioka; Masaru Motojima
Journal:  Nephron Exp Nephrol       Date:  2003
View more
  3 in total

1.  Nanomedicine: Addressing Cardiovascular Disease and Cardiovascular Tissue Regeneration.

Authors:  Rebekah A Neal; Olugbemisola Oredein-McCoy; Edward A Botchwey
Journal:  Curr Bioact Compd       Date:  2009

2.  Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells.

Authors:  Diana Lanza; Alessandra F Perna; Adriana Oliva; Raymond Vanholder; Anneleen Pletinck; Salvatore Guastafierro; Annarita Di Nunzio; Carmela Vigorito; Giovambattista Capasso; Vera Jankowski; Joachim Jankowski; Diego Ingrosso
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

3.  Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics.

Authors:  Yoric Gagnebin; David A Jaques; Serge Rudaz; Sophie de Seigneux; Julien Boccard; Belén Ponte
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.